<DOC>
	<DOCNO>NCT01390402</DOCNO>
	<brief_summary>The goal clinical research study learn give kind immune cell call natural killer ( NK ) cell chemotherapy improve response stem cell transplant patient CML . The safety treatment also study .</brief_summary>
	<brief_title>Alloreactive Haploidentical Natural Killer ( NK ) Cells With Busulfan Fludarabine/ATG</brief_title>
	<detailed_description>NK cell may react leukemia cell , particularly mismatch certain HLA tissue type protein . In lab , NK cell separate blood use machine call CLINIMACs system . This machine use certain kind cell antibody-coated magnetic bead separate NK cell . The drug aldesleukin ( interleukin-2 , IL-2 ) add NK cell improve function . The aldesleukin wash cell sample give . The NK cell donate family member certain genetic type blood call HLA partly match . The stem cell receive come separate HLA-identical family member unrelated donor . Fludarabine design interfere DNA ( genetic material ) cancer cell , may cause cancer cell die . Busulfan design bind DNA , may cause cancer cell die . Study Drug Administration : If find eligible take part study , 6 day NK cell infusion , admit hospital receive hydration fluid vein . Starting 5 day NK cell infusion , receive fludarabine vein 1 hour 4 day row . On last 2 day , receive busulfan vein 3 hour . The day NK cell infusion , `` rest '' ( receive drug ) . Starting 3 day infusion , receive methylprednisolone vein 15 minute antithymocyte globulin ( ATG ) vein least 4 hour 3 day row . ATG give help reduce risk transplant rejection . On day NK cell infusion , receive NK cell vein . You receive Benadryl ( diphenhydramine ) vein 15 minute infusion help low risk allergic reaction . Starting day NK cell infusion , receive aldesleukin injection skin 1 time day 5 day . Aldesleukin give help NK cell survive multiply . Starting 5 day NK cell infusion , receive ATG vein 1 time day 3 day . The day last ATG dose , receive stem cell transplant vein . You also receive tacrolimus methotrexate help low risk reaction call graft vs. host disease ( GVHD ) . GVHD donate immune cell transplant react body person receive cell . You receive tacrolimus vein continuous infusion 2 week stem cell transplant . After , receive tacrolimus mouth 1 time day least 3 month . On Days 1 , 3 , 6 stem cell transplant , receive methotrexate vein 30 minute . You also receive Neupogen ( filgrastim , G-CSF ) injection skin 1 time day blood cell count high enough . Study Tests : On Day 5 NK cell infusion , blood ( 2 tablespoon ) draw check NK cell . During study , blood ( 2 tablespoon ) draw 1 time check protein find NK cell . This blood collect routine blood draw , possible , avoid additional needle stick . If central venous catheter ( CVC ) , blood drawn CVC . You need stay hospital 4 week blood draw ( 2 teaspoon ) routine test often doctor think need time . After leave hospital , continue outpatient hospital area , mean stay close enough able come back visit least 100 day transplant . Length Study : You take study early disease get bad , intolerable side effect occur , enough NK cell collect , unable follow study direction . Your participation study complete follow-up phone call . Long-Term Follow-Up : At 1 , 3 , 6 , 12 month transplant : - You physical exam . - You ask side effect may . - You check possible reaction treatment , include GVHD graft failure . Graft failure occur donor cell may able grow multiply body . If happens , high risk infection and/or bleed . If number white blood cell get back high enough level within 3 week transplant , stem cell may need give . - Blood ( 4 tablespoon ) draw routine test check level infuse NK cell , immune function test , check status disease . - If doctor think need , bone marrow aspiration check status disease . One ( 1 ) time year 2 year transplant , unable return follow-up visit , study staff call ask . These phone call take 10 minute . This investigational study . The way researcher process NK cell use CliniMACs device investigational . The NK cell process FDA approve commercially available . It currently use research purpose . Fludarabine busulfan FDA approve commercially available treat CML . Up 32 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Patients meet follow eligibility criterion eligible inclusion study . Pediatric team ass eligibility appropriate patient age . 2 . Age &lt; /= 70 year age . 3 . Patients diagnosis CML first chronic phase accelerate phase le 15 % blast blood bone marrow study entry fail respond adequately imatinib consensus criterion Baccarani et al : ) hematologic remission 3 month , b ) cytogenetic response 6 month , c ) major cytogenetic response 12 month , ) complete cytogenetic response major molecular response &gt; 18 month , e ) loss response increase cytogenetic molecular evidence disease . Or intolerant tyrosine kinase inhibitor therapy . Or second great chronic phase ( prior transformation respond treatment &lt; 15 % blast study entry ) . 4 . Histocompatible stem cell donor : Patients must HLA match related unrelated donor ( HLA A , B , C DR ) willing donate allogeneic hematopoietic transplantation . 5 . Haploidentical NK cell donor : Patients must haploidentical relative absence KIRligand ( HLA molecule ) . 6 . Performance status : Zubrod &lt; /= 2 Lansky PS great equal 70 % . 7 . Cardiac function : leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmia uncontrolled symptomatic cardiac disease . 8 . Pulmonary function : symptomatic pulmonary disease . forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffusion capacity lung carbon monoxide ( DLCO ) &gt; /= 50 % expect , correct hemoglobin . For pediatric patient , unable perform pulmonary function test ( child &lt; 7 year age ) , pulse oximetry &gt; /= 92 % room air pulse oximetry . 9 . Renal function : Serum creatinine &lt; /= 1.8mg/dl creatinine clearance great equal 40 cc/min . Creatinine pediatric patient &lt; /= 1.5 mg/dl &lt; /= 2 time upper limit normal age ( whichever less ) . 10 . Liver function : Bilirubin &lt; /= 1.5 mg/dl ( unless Gilbert 's syndrome ) , ALT AST &lt; /= 200 IU/ml adult unless related underline disease . For pediatric patient conjugate ( direct ) bilirubin &lt; 2x upper limit normal , ALT AST &lt; 5 time upper limit normal.No evidence chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Study Chairman consider liver biopsy . 11 . Patient patient 's legal representative , parent ( ) guardian able provide write informed consent . Assent age appropriate . 1 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . The Protocol PI final arbiter eligibility . 2 . Pleural/pericardial effusion ascites estimate &gt; 1L 3 . HIVpositive . 4 . Breast feeding pregnancy . Pregnancy mean positive beta human chorionic gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 5 . Known allergy mouse proteins 6 . Active hepatitis B C infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alloreactive haploidentical NK cell</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Immune cell</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Human leukocyte antigen</keyword>
	<keyword>HLA</keyword>
	<keyword>Graft-vs-host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Methotrexate</keyword>
</DOC>